Zobrazeno 1 - 10
of 194
pro vyhledávání: '"Jean Sebastien FRENEL"'
Autor:
Elsa Curtit, Martine Marie Bellanger, Virginie Nerich, Delphine Hequet, Jean-Sebastien Frenel, Olivier Cristeau, Roman Rouzier
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionChemotherapy (CT) is commonly used as an adjuvant treatment for women with early breast cancer (BC). However, not all patients benefit from CT, while all are exposed to its short- and long-term toxicity. The Oncotype DX® test assesses ca
Externí odkaz:
https://doaj.org/article/c87ffa5b5cd743ce8a6acba397bb5d2c
Autor:
Amandine Billaud, Louise-Marie Chevalier, Paule Augereau, Jean-Sebastien Frenel, Christophe Passot, Mario Campone, Alain Morel
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-14 (2021)
Abstract Background Targeted therapies in oncology are promising but variants of uncertain significance (VUS) limit their use for clinical management and necessitate functional testing in vitro. Using BRCA1 and BRCA2 variants, which have consequences
Externí odkaz:
https://doaj.org/article/79c1e3cddf6545f2a4bd74aab526e620
Autor:
Ke Zhou, Martine Bellanger, Sophie Le Lann, Marie Robert, Jean-Sebastien Frenel, Mario Campone
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposePatient-reported outcomes (PROs) have been widely used to measure breast cancer (BC) treatment outcomes. However, evidence is still limited on using routinely PROs to personalize treatment decision-making, including or not chemotherapy, target
Externí odkaz:
https://doaj.org/article/a8d331394c49474f81479554691a6e46
Autor:
Marion Alhenc-Gelas, Luc Cabel, Frederique Berger, Suzette Delaloge, Jean-Sebastien Frenel, Christelle Levy, Nelly Firmin, Sylvain Ladoire, Isabelle Desmoulins, Pierre-Etienne Heudel, Florence Dalenc, Delphine Loirat, Coraline Dubot, Perrine Vuagnat, Elise Deluche, Meriem Mokdad-Adi, Anne Patsouris, Josselin Annic, Lounes Djerroudi, Marion Lavigne, Jean-Yves Pierga, Paul Coppo, Francois-Clement Bidard
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-10 (2021)
Abstract Background Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multicentre study focusing o
Externí odkaz:
https://doaj.org/article/f7239abd3511401b9773a7aef4c9d1ce
Autor:
Mathilde Richard, Jean Sebastien FRENEL, Laurent Mathiot, Mario Campone, Mathilde Colombie, Marie Robert, Anne Patsouris, Frederic Bigot, Julie Gavard, Gwennan André-Grégoire, Laetitia Guevel
Publikováno v:
Cancer Research. 83:P3-11
CONTEXT: Endocrine therapy combined with CDK4/6 inhibitor is the standard frontline treatment for the vast majority of HR+/HER2- metastatic breast cancer (MBC) patients. Despite an overall survival benefit, patients eventually progress and mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0c822ba4ae8e7be3b3c65017d1d19a0
https://doi.org/10.1158/1538-7445.sabcs22-p3-11-09
https://doi.org/10.1158/1538-7445.sabcs22-p3-11-09
Autor:
Emeline, Colomba, Jérôme, Alexandre, Gwénaël, Le Teuff, Catherine, Genestie, Dahna, Coupez, Isabelle Ray, Coquard, Pierre Emmanuel, Brachet, Sixtine, de Percin, Christophe, Sajous, Michel, Fabbro, Nicolas, Delanoy, Florence, Joly, Jean Sebastien, Frenel, Patricia, Pautier, Alexandra, Leary
Publikováno v:
Gynecologic Oncology. 169:78-84
Around 15% of metastatic endometrial carcinoma (EC) are MMRd/MSI-H improving response to immune checkpoint inhibitors (ICI). So far, few data existed considering the chemotherapy (CT) sensitivity in MMRd/MSI-H EC, especially response to first-line pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e1dcbaa6573f8d88a27ec68f4eef1c
https://doi.org/10.1016/j.ygyno.2022.11.029
https://doi.org/10.1016/j.ygyno.2022.11.029
Autor:
Sara A Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, José Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés
Publikováno v:
The lancet : international edition
Background An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer in the progression-free survival interim analysis of the DESTINY-Breast0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f34ca39bb4e6f5a2f1a4d78197528f6d
https://doi.org/10.1016/s0140-6736(22)02420-5
https://doi.org/10.1016/s0140-6736(22)02420-5
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Recently many therapeutic classes have emerged in advanced hormone receptor-positive breast cancer, which is the leading cause of cancer death in women. In absence of visceral crisis, treatment relies on endocrine therapy combined with cyclin depende
Externí odkaz:
https://doaj.org/article/8b1b051acf4145d58d96075668e7bba1
Autor:
Mathilde Colombié, Pascal Jézéquel, Mathieu Rubeaux, Jean-Sebastien Frenel, Frédéric Bigot, Valérie Seegers, Mario Campone
Publikováno v:
Cancer Research. 82:OT1-20
Background: Each year 5 to 10% of new breast cancers are diagnosed with a metastatic staging. Metastatic breast cancer remains an incurable disease despite significant therapeutic advances in both supportive cares and targeted specific therapies. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a8f5e61ec68c11cba72bdac1fa53260
https://doi.org/10.1158/1538-7445.sabcs21-ot1-20-01
https://doi.org/10.1158/1538-7445.sabcs21-ot1-20-01
Autor:
Jean-Sebastien Frenel, Séverine Guiu, Dominique Debiais, Isabelle Moley-Massol, Laure Gueroult-Accolas, Claudia Lefeuvre-Plesse
Publikováno v:
Cancer Research. 82:P5-15
Metastatic breast cancer (mBC) progression and associated treatments can significantly impact the patients’ quality of life (QoL). However, few studies address the patients’ experience and the solutions to improve their QoL. RÉALITÉS 2 is a phy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e045ed629b9cd2eca53839f5ce2f80b9
https://doi.org/10.1158/1538-7445.sabcs21-p5-15-06
https://doi.org/10.1158/1538-7445.sabcs21-p5-15-06